Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2003

View Archived Issues

Clinical benefits of efalizumab in plaque-type psoriasis

Good efficacy and safety profile reported for arzoxifene in hormone-sensitive breast cancer

New NK1 antagonists identified by Kyorin researchers

Novartis presents new PTP1B inhibitors in a recent patent

Spanish researchers prepare and test novel cannabinoid CB1 antagonists

Sumitomo claims TGF-beta antagonists with potential in fibrotic disorders

New EGFR inhibitors discovered at Boehringer Ingelheim

Ono claims novel prostanoid DP antagonists, their preparation and use

Pfizer scientists describe novel PPARgamma ligands and their use

Phase I trial begins for ChimeriVax-West Nile vaccine

Gene expression profiling for classifying pediatric ALL

Candidate gene for obesity located by international research team

Parkinson's disease: important genetic findings and RNAi-based drug development

Final results for phase II study of R-1549 in gastric cancer

Positive long-term data obtained for Aryplase

Rat study results for injectable sustained-release ZT-1 for Alzheimer's disease

Green light for phase I/II study of Enzo's gene vector for HIV

Guilford announces positive phase II results for Aquavan

Completion of first clinical study of Durect's postoperative pain depot product

Edaravone has beneficial effects in LPS-induced liver damage

Sativex marketing agreement extended to Canada

Shire and Noven work towards MethyPatch approval

Xcytrin evaluated in combination with Rituxan and Zevalin

Intranasal QR-435 prevents influenza infection in ferrets

Spotlight on systemic lupus erythematosus

Neuroprotective efficacy of neurosteroid in spinal cord ischemia

VP-025 prevents LPS-induced LTP impairment in rat brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...